Compare TNXP & CVGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | CVGI |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.7M | 167.7M |
| IPO Year | 2008 | 2004 |
| Metric | TNXP | CVGI |
|---|---|---|
| Price | $9.92 | $4.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 544.8K | ★ 604.3K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.75 | ★ 316.18 |
| EPS | N/A | ★ 0.04 |
| Revenue | $13,107,000.00 | ★ $755,231,000.00 |
| Revenue This Year | $558.11 | $4.84 |
| Revenue Next Year | $38.29 | $5.36 |
| P/E Ratio | ★ N/A | $116.25 |
| Revenue Growth | ★ 29.85 | 14.06 |
| 52 Week Low | $10.03 | $1.29 |
| 52 Week High | $69.65 | $5.88 |
| Indicator | TNXP | CVGI |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 48.56 |
| Support Level | N/A | $4.69 |
| Resistance Level | $13.18 | $5.77 |
| Average True Range (ATR) | 0.93 | 0.28 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 1.20 | 41.98 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.